Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Don't they realise that the virus is about to check out of its own accord?
Just like MERS and SARS did.
Hi HB.
Well, If NWBO read the Board, then we have tipped them the wink, to get on and protect their trademark.
I know it doesn't give us the answer, but I like the analysis.
That's a sharp suit you're wearing.
Hi Abeta. That's a bit of a cheek, what they're calling it:-
The Cov-DCVax vaccine is intended for generating long-lasting protective immunity in high risk individuals, while the viral antigen-specific T cells provide immediate therapeutic protection in controlling the progression of COVID-19-associated disease
Yes, no evidence of a manufacturing site licence having been granted yet.
The list of these is updated monthly, but runs in arrears as well.
I've been watching for quite a while now...
I'd really like to know what site activity is going on right now.
Whoops.
What I thought was unusual was that the price appreciation continued right up until Fri close. No profit taking.
This is not just swing traders.
On that basis, I see no reason for a dip on Tue morning.
I think a further rise is more likely.
But how much more wind is in the sails, who can say?
Because of crossover, treatment / control delta is devilishly difficult.
Try and get mine up by about Wed.
Don't forget we're doing meth and unmeth as well!
Just a bit of fun.
Ahah, thanks VuBru.
Maybe it wasn't Smiffy, then.
Do we know anything about Columbine Capital Services?
They were right on 'Outperform'!
Something tells me they're not quite Oppenheimer though...
I remember CCS.
Top of the Pops, Thursday nights..
Well, yes indeed, meirluc!
One thing it ain't is chemotherapy..
Regards.
(I'm going to have a stab at arm-by-arm OS next week; OS24, OS36, OS60. And with meth / unmeth breakdown. Purely for fun and to see how close I can get. Be interested if you want to have a go. Gotta do it soon, otherwise I'll be in danger of after-timing.)
Well, it's good old Larry or nobody.
In his latest piece he gives a 'Buy' recommendation, but I can't see a 12 month price forecast.
Sure ain't AF.
https://smithonstocks.com/northwest-biotherapeutics-nwbo-buy-0-26-detailed-results-for-the-phase-3-dcvax-l-trial-in-ndgbm-are-imminent/
Yes, it's auto-generated, but the one analyst they list as giving a rating is probably Larry Smith, don't you think?
NWBO - The Only Real Cancer Chemotherapeutic Platform....
That Is Logical, Cost Effective, & Easy To Implement...
And, Designed Perfectly, By Nature, To Perform As No Other Existing Therapy Has Done Or Will Be Capable Of.....
Very Long This Gift Of Nature To Human Cancer Cure...
I think most technicians would say retrenching say to the $.28 area before advancing again is healthy.
OK. I was wrong. It is a word.
But I still think he meant lucid!
(And I doubt he has read the full version..)
I take it Mr Rago means 'lucid'.
Lucent isn't a word...
P.S., if you have spare cash invest in booze, illegal drugs and the local whore house.
Yes, but where do you think topline fits into all that?
Hey, it was our research!
Lol.
Nothing there to say that some of the funds would be devoted to Direct.
You could say that the choice of language might perhaps lead some listeners to take it to mean that they are full steam ahead on everything.
But that is, to some extent, a function of what readers want to read, rather than what is written, imo.
P3 trial: 'move forward'
Direct: 'look forward'
As soon as I see 'look forward', I take it to mean nothing happening any time soon. They are communicating that they haven't forgotten Direct, they still have it on the horizon, but that is all.
Actually 'looking forward to moving forward' is quite a turn of phrase.
And if you said it was an example of lawyer speak I wouldn't disagree with you. And I would prefer that they were a bit straighter. Something like: 'all essential P3 expenditure will be prioritised over everything else'.
Maybe you just get attuned to this type of corporate speak after a while. I'm sure it's the rule rather than the exception in this small bio field.
When did they ever say that a specific proportion of the war chest would be reserved for getting Direct trials going?
I think most of us here know that whatever it takes to get L over the line, was and is the only priority.
Just to be devil's advocate, Senti; what are those steps?
I suppose you could try switching the computer off at the mains before rebooting and trying again a few times, if you don't like the first readout.
The data is what the data is, and has to be applied to the statistical analysis, as described in the SAP, which had to have been finalised before unblind.
Seriously, I know what LP said, but I really don't know what these other time-consuming steps (while the data remains solely with the Stats) actually are. Yes, you would want to run maybe hundreds of subtests that would enable you to identify and quantify positive outcomes in sub-populations (such as older trial subjects, who have done particularly well in this trial, compared to expectation)
I don't see why there is any imperative for the company to remain blinded, while the unblinded data is with the Stats. Obviously company folk won't be able to calculate p values and such like, but if I was in LP's shoes, I would want to give myself the maximum time to consider the implications of the data, and then to reach a resolve as to how the company will go forward with the data, what will go in a topline announcement, how it will be presented, and how the company will move forward beyond that.
I can see an ongoing dialogue with the Stats as being useful (for example, around the relative statistical strength of meth v unmeth data), but I don't get the 'first them, before us' approach.
Maybe it's just normal protocol for the Stats to get first look.
Nobody knows!
It will surely follow the same way..
Reardon basically said or implied as much.
OK. Assuming we started Mon a.m. at 0.17 ( we usually did), my abacus calculates that as a 41% rise on the week.
Today's rise was on pretty piddling volume in the scheme of things.
Which tells me this bit of money is not from where the MM's normally see it from.
It also tells me that the previous 0.17 'lockdown' was just an artifice created by the MM's.
He's two thirds full today.
Hi Sharpie.
Well, that's the final nail in the coffin for ICI's as monotherapies for GBM.
Did you notice that LL wrote the editorial on the trial, also released in JAMA today?
Full version only available to bona fide subscribers (unless you access it a different way..)
https://jamanetwork.com/journals/jamaoncology/article-abstract/2766209
So it was recurrent GBM and I'm not sure how you can have PFS with rGBM, but anyway, the Nivo arm was 1.5 months and the Bev arm was 3.5 months. Basically, extremely bad v very bad.
And on OS, Bev did slightly better than Nivo; 10.00 v 9.8 months.
And we already know the, ermm, limitations of Bev...
No reason to think that Pembro is any different or any better than Nivo.
Honestly, in our combo trial with Pembro, I expect L to do better than L plus Pembro.
LL is quoted as saying in the editorial:-
"The future of defeating this opponent will depend on a better elucidation of the mechanisms by which antitumor immune responses are generated in the central nervous system, as well as the identification of predictive biomarkers of response," they wrote. "It is anticipated that the next generation of clinical trials of immunotherapy for patients with glioblastoma would involve new strategies that build on the data and insights from the large multicenter phase 3 studies that have gone before."
Do not want anything that resides in the cloud.
I would prefer that input of raw data to stat software is done offline.
If a leak, or a hack, happens, it will be between unblind and topline.
Hargreaves Lansdown and an up to date W-8 BEN form.
Steady on; you'll spill it..
It won't tell the world at large a lot, except that they've done it.
So hardly a huge material event to Mr Market.
But it is significant to those afficianados who are in the know (like yours truly)
Lol.
The significance is that they will have cleared all the goddamn queries. The CRO will basically have finished their decade long job of running the trial.
Timescales will be back in their hands, and they can give the unblinded data to the Stat guys and gals for 3 weeks (and pretend they haven't peeked themselves).
Honestly, there is absolutely no need for the stats to have the unblinded data exclusively for 2 or 3 weeks.
What the hell are they going to do with it for so long.?
If and when they unblind, that means the SAP is de facto final; no more tweaking.
So all the stats have to do is apply the unblinded data to the analysis as described in the SAP.
Plug the data into the stat software, and, eh voila, out comes your results.
Though if they are still on Windows '98 or earlier, it might take a bit longer.
Basically, it'll be a relief when they release news of datalock.
If they release news of datalock. I'm not at all convinced they will PR it the day it happens.
But when it is confirmed as having happened, it'll mean the trial has ended!
And it'll mean that we will get results a month or two later.
So actually quite a momentous moment for those that have been on the journey for a while.
Took it for 19 years....
Didn't anyone tell her it's dangerous?
Lol.
Thankyou, Ex.
So it's a fundamentally good idea to ensure access to working capital?
Like, er, really important...
And failure to be able to do so would probably result in the ultimate dilution to retail shareholders?
100%?
So why do you think that there are opinions expressed frequently that appear to suggest that raising working capital is a bad thing?
If it's the price that matters, then that presumably means that they should endeavour to raise necessary funds on the best terms.
Are they doing that?
Are there funds that they can access elsewhere on better terms?
Anyway, the important thing is that they are currently able to find ways to ensure working capital is available.
Long may it continue.
I have no intention of ever attempting to understand the intricacies of US financial filings, on the basis that life is too short..
But Ex; perhaps you could summarise for me?
Does this 8K mean that they have found a route to access some short term working capital?
If so, how much?
It'll be great news if this indeed the case. It presumably means they can remain a going concern.
When and if all their sources of working capital dry up completely, what would it mean?
Would it mean they have to shut up shop?
And if they have to shut up shop (file for bankruptcy?), can you predict the dilutive effect that would have on the average retail investor?
Ta in anticipation.
While you're still pursuing this, here's another link for you. "Hydroxychloroquine Has about 90 Percent Chance of Helping COVID-19 Patients, States Association of American Physicians and Surgeons (AAPS)"
https://www.globenewswire.com/news-release/2020/04/28/2023542/0/en/Hydroxychloroquine-Has-about-90-Percent-Chance-of-Helping-COVID-19-Patients-States-Association-of-American-Physicians-and-Surgeons-AAPS.html
You do advise listening to doctor's, right?
I think your glass needs topping up, JD.
One person's indicative evidence is another person's anecdote.
I never use 'anecdotal' these days because it's been somewhat hijacked by the likes of the AF's (both of them!) and has taken on somewhat dismissive or derogatory overtones.
And I try to not use it for debates on this Board, as I think it has a somewhat stifling effect. I'm all for a no holds barred, but respectful interchange.
I think you have to look to your own answers for the US.
IMO, in respect of the virus, you have something akin to a loose confederation, with individual states taking their own approach. This makes it very difficult to make valid nationwide generalisations.
But, at the national level, you don't have more infections and deaths per capita, anyway. Certainly not compared to most of northern Europe.
You have a state patchwork, with hugely varying case incidence and mortality.
Obviously the NY state / California comparison is interesting because of the hugely stark difference in cases and fatalities.
And use or non-use of HC would hardly explain that.
We have discussed the particular circumstance in NY to quite a degree. And I doubt whether use or non-use of HC would have made much difference at least in the first 2 months in NY. The tsunami of cases and deaths was just a feature of the epidemic that prevailed at that time at that location.
You're right to say that use of HC became a politicised issue. But that was also my observation from a standpoint outside of your situation.
It shouldn't be this way, but it is.
I hope that countries further afield, such as much of Asia, S. America, and Africa can make their own decisions about what treatments should be employed based on their own experience and their own circumstance, without being affected by the politicisation.
On causality, I didn't assert any causality. I simply pointed out some facts. You could say I inferred possible causality, and I wouldn't bother to argue that point, because there was implicit inference! It's up to others to decide for themselves on causality or non-causality.
It’s cause “liberals” or “media bias” or some such nonsense.
Well, I stand entirely outside the US political scene, but I can't fail to notice how some opinions fall along party lines.
The treatment of Covid patients should not be impacted by partisan politics.
And in the UK, the whole lot of them are an absolute waste of space.